. . . . . . . "[Reported results from clinical trials in metastatic colorectal, metastatic renal and hormone-refractory prostate cancer patients demonstrate that MVA-5T4 is safe and highly immunogenic, both as a monotherapy and in combination with standard-of-care therapies including irinotecan, oxaliplatin, IFN-alpha and IL-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:13:46+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .